Voyager Pharmaceutical Corporation Completes Second Phase II Clinical Study For Alzheimer's Disease
Thu, 04 May 2006 06:00 AM EST
... Voyager Pharmaceutical Corporationannounced Wednesday the completion of a Phase II study that assessed thesafety and efficacy of leuprolide acetate in the treatment ofmild-to-moderate Alzheimer's disease in men. The 48-week study, known as VP-AD-104, was a double-blind, placebo-controlled, multi-center study... click link for more info. ...
Related Topics
- Clinical Trials
- Alzheimer's Disease
- Infectious Diseases
- Alzheimer's Caregivers
- Crohn's Disease
- Cardiovascular Diseases And Disorders
- Pharmacology
- Psychopharmacology
- Alzheimer disease
- Nonoxynol-9
- Peptic Ulcer
- Diseases & Conditions
- Nystatin and Triamcinolone
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Clinical Growth Charts
- Epidemiology
- Heart Disease
- Bone Disease
- Phenylketonuria

Not Signed In -


